A comprehensive view of MannKind Corp.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

MannKind acquires Zealand Pharma’s V-Go wearable insulin delivery device for US$10M, as Zealand refocuses priorities on R&D; V-Go joins MannKind’s diabetes portfolio, including rapid-acting Afrezza inhaled insulin product

Inhaled therapeutic firm MannKind Q1 net loss widens to US$26.0M from US$12.9M a year ago, with total revenues down to US$12.0M from US$17.4M a year ago; Afrezza inhaled insulin sales up 21%, as collaborations and services costs increase, revenue falls

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count